Your shopping cart is currently empty

ATPγS tetralithium salt is a good substrate for RNA-stimulated nucleotide hydrolysis and RNA unwinding activity of eIF4A.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $67 | In Stock | In Stock | |
| 5 mg | $161 | In Stock | In Stock | |
| 10 mg | $278 | In Stock | In Stock | |
| 25 mg | $593 | In Stock | In Stock | |
| 50 mg | $1,020 | In Stock | In Stock | |
| 100 mg | $1,770 | - | In Stock |
| Description | ATPγS tetralithium salt is a good substrate for RNA-stimulated nucleotide hydrolysis and RNA unwinding activity of eIF4A. |
| In vitro | ATPγS tetralithium salt enhances intrinsic fluorescence and induces aggregation, thereby increasing spinach Rubisco activating enzyme activity. The concentration dependence of the ATPγS tetralithium salt effect is S-shaped, but at pH 8, the half-saturation requirement of ATPγS tetralithium salt (12 μM) is consistent with that measured indirectly using the fluorescent probe 1-anilinolyl-8-sulfonate. The binding affinities (6 μM) are not much different. [2] |
| In vivo | METHODS: A mouse model of ALI induced by intratracheal administration of endotoxin/lipopolysaccharide (LPS) and cultured lung ECs was used and treated with ATPγS tetralithium salt (50-100 μM final blood concentration). RESULTS ATPγS tetralithium salt attenuated the inflammatory response, reduced the accumulation of cells (48%, P < 0.01) and proteins (57%, P < 0.01) in bronchoalveolar lavage fluid, and reduced neutrophil infiltration and Evans blue albumin dye extravasation into lung tissue. [3] |
| Synonyms | ATP-gamma-S tetralithium salt |
| Molecular Weight | 546.98 |
| Formula | C10H12Li4N5O12P3S |
| Cas No. | 93839-89-5 |
| Smiles | O[C@H]1[C@@H](O[C@@H]([C@H]1O)COP(OP(OP([O-])([S-])=O)([O-])=O)([O-])=O)N2C3=NC=NC(N)=C3N=C2.[Li+].[Li+].[Li+].[Li+] |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | H2O: 25 mg/mL (45.71 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.